Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, St Leonards, NSW, 2065, Australia.
Northern Clinical School, Sydney Medical School, University of Sydney, St Leonards, NSW, Australia.
Neurocrit Care. 2019 Jun;30(3):534-541. doi: 10.1007/s12028-018-0566-0.
Consensus on appropriate outcome measures to use in aneurysmal subarachnoid hemorrhage (aSAH) research has not been established, although the transition toward a core outcome set (COS) would provide significant benefits. To inform COS development, we conducted a systematic review to identify outcome measures included in reports of randomized clinical trials (RCTs) of interventions in patients with aSAH. Ovid Medline, EMBASE, CINAHL, and CENTRAL were searched. RCTs investigating aSAH published between January 1996 and May 2015 were included. The primary and secondary outcomes of RCTs were recorded and classified according to the OMERACT Consortium's framework. We identified 1093 potential studies of which 129 met inclusion criteria representing 24 238 patients. There were 285 unique outcome measures. The Glasgow Outcome Scale (GOS) was the most frequently used primary outcome (13/129, 10.1%). Mortality was reported in 84 trials (65.1%) with 3 months the most common time point (34/129, 26.4%). The GOS (65/129, 50.4%) and the Modified Rankin Scale (51/129, 39.5%) were the most commonly reported functional measures; however, these were reported at different time points and often dichotomized using different ranges. Patient-reported quality of life measures were used in 11 trials (8.5%). Transcranial Doppler was the most frequently used imaging modality (40/129, 31.0%). Definitions and reporting of vasospasm, delayed cerebral ischemia and imaging modality results were highly variable. The marked heterogeneity of outcomes in reports of RCTs supports the development of a core outcome set for aSAH trials. Our study has identified a wide range of outcomes for potential inclusion in a future aSAH COS.
在颅内动脉瘤性蛛网膜下腔出血(aSAH)研究中,尚未建立适当的结局测量标准,尽管采用核心结局测量标准(COS)将带来显著的益处。为了制定 COS,我们进行了一项系统评价,以确定纳入 aSAH 患者干预随机临床试验(RCT)报告中的结局测量标准。我们检索了 Ovid Medline、EMBASE、CINAHL 和 CENTRAL。纳入了 1996 年 1 月至 2015 年 5 月发表的 aSAH RCT 研究。记录并根据 OMERACT 联合会的框架对 RCT 的主要和次要结局进行分类。我们共确定了 1093 项潜在研究,其中 129 项符合纳入标准,共涉及 24238 例患者。共纳入了 285 个不同的结局测量标准。格拉斯哥结局量表(GOS)是最常使用的主要结局测量标准(13/129,10.1%)。有 84 项试验(65.1%)报告了死亡率,其中 3 个月是最常见的时间点(34/129,26.4%)。GOS(65/129,50.4%)和改良 Rankin 量表(51/129,39.5%)是最常报告的功能测量标准;但是,这些指标在不同的时间点进行报告,且常常使用不同的范围进行二分法。11 项试验(8.5%)使用了患者报告的生活质量测量标准。经颅多普勒是最常使用的影像学方法(40/129,31.0%)。血管痉挛、迟发性脑缺血和影像学结果的定义和报告高度可变。RCT 报告中结局的显著异质性支持制定 aSAH 试验的核心结局测量标准。我们的研究已经确定了广泛的结局指标,可纳入未来的 aSAH COS。